Plasma Cell Leukemia
📧 Sign up to get email alerts when something new happens for Plasma Cell Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-03Clinical Trial Update: IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia [Phase 2]
Phase 2 clinical trial evaluating IL-15-Armored CAR-T therapy in relapsed or refractory multiple myeloma and plasma cell leukemia; currently…
-
CLINICAL_TRIALS trial_result · 2025-09-19Clinical Trial Update: Treatment of Primary Plasma Cell Leukaemia in Subjects Under the Age of 70 [Phase 2]
This update reports the completion of a Phase 2 clinical trial evaluating treatment for primary plasma cell leukemia in patients under 70.
-
CLINICAL_TRIALS trial_result · 2025-05-09Clinical Trial Update: Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma [Phase 2]
Phase 2 trial evaluating cord blood-derived natural killer cells in combination with elotuzumab, lenalidomide, high-dose melphalan, and stem…
-
CLINICAL_TRIALS trial_result · 2025-03-18Clinical Trial Update: Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma [Phase 2]
A Phase 2 trial evaluating a conditioning regimen with panobinostat, gemcitabine hydrochloride, busulfan, and melphalan before stem cell tra…
-
CLINICAL_TRIALS trial_result · 2024-12-12Clinical Trial Update: a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia [EARLY_Phase 1]
Early-phase 1 clinical trial of CT0596 for relapsed/refractory multiple myeloma and relapsed/refractory plasma cell leukemia is currently re…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-09-21Clinical Trial Update: Allo HSCT Using RIC for Hematological Diseases [Phase 2]
Phase 2 trial evaluating allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning for various hematologic dise…
-
CLINICAL_TRIALS trial_result · 2022-11-03Clinical Trial Update: Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies [Phase 2]
Phase 2 clinical trial update on shorter course tacrolimus after non-myeloablative conditioning with related donor PBSCT and high-dose postt…
-
CLINICAL_TRIALS trial_result · 2022-05-23Clinical Trial Update: Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia [Phase 2]
Phase 2 trial evaluating pomalidomide, ixazomib, and dexamethasone in patients with previously treated multiple myeloma or plasma cell leuke…
-
CLINICAL_TRIALS trial_result · 2020-10-19Clinical Trial Update: A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]
Clinical trial update for ARRY-520 in relapsed or refractory multiple myeloma completed phases 1 and 2.
-
CLINICAL_TRIALS trial_result · 2019-12-20Clinical Trial Update: Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating total-body irradiation and fludarabine phosphate followed by donor peripheral blood stem cell transpla…
-
CLINICAL_TRIALS trial_result · 2019-05-29Clinical Trial Update: Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia [Phase 2]
Phase 2 clinical trial evaluating autologous peripheral blood stem cell transplant followed by donor bone marrow transplant in high-risk B- …
-
CLINICAL_TRIALS trial_result · 2016-02-03Clinical Trial Update: Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma [Phase 1, Phase 2]
The National Cancer Institute–sponsored Phase 1/2 trial evaluating carfilzomib with stem cell transplantation for plasma cell myeloma was te…
-
CLINICAL_TRIALS trial_result · 2014-12-11Clinical Trial Update: Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen [Phase 2]
A Phase 2 trial assessing stem cell transplantation using a reduced-toxicity myeloablative conditioning regimen for high-risk multiple myelo…
-
CLINICAL_TRIALS trial_result · 2014-09-11Clinical Trial Update: Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL) [Phase 1, Phase 2]
Phase 1/2 safety and tolerability study of SNS01-T in relapsed or refractory B-cell malignancies sponsored by Senesco Technologies. The tria…
-
CLINICAL_TRIALS trial_result · 2013-10-24Clinical Trial Update: Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants [Phase 2]
Phase 2 trial evaluating a conditioning regimen of bortezomib followed by high-dose melphalan and bortezomib for tandem stem cell transplant…
-
CLINICAL_TRIALS trial_result · 2013-04-29Clinical Trial Update: Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia [Phase 1]
This Phase 1 trial assessed the combination of arsenic trioxide and ascorbic acid with bortezomib, thalidomide, and dexamethasone in patient…
-
CLINICAL_TRIALS trial_result · 2012-03-14Clinical Trial Update: Lenalidomide and Dexamethasone in Primary Plasma Cell Leukemia [Phase 2]
A Phase 2 clinical trial evaluating lenalidomide and dexamethasone in primary plasma cell leukemia has completed.
-
CLINICAL_TRIALS trial_result · 2011-09-22Clinical Trial Update: Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia [Phase 2]
Phase 2 trial evaluating a combination of bortezomib, liposomal doxorubicin, and dexamethasone for plasma cell leukemia, with multiple myelo…